4D Molecular Therapeutics, Inc. (FDMT) Net margin 2019–2025
4D Molecular Therapeutics, Inc. (FDMT) net profit margin by fiscal year — reported net income divided by reported revenue.
-164.4%FY2025 · since FY2019: -708.4% → -164.4%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -164.4% | +434613.9 pp |
| FY2024 | -434778.4% | -434291.8 pp |
| FY2023 | -486.6% | +2948.8 pp |
| FY2022 | -3435.4% | -3040.0 pp |
| FY2021 | -395.4% | +28.9 pp |
| FY2020 | -424.3% | +284.2 pp |
| FY2019 | -708.4% | — |
Net margin = reported net income ÷ reported revenue for the same fiscal year. Loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice
More FDMT financial trends
FDMT RevenueFDMT Net incomeFDMT Gross profitFDMT Gross marginFDMT Operating incomeFDMT Operating marginFDMT Operating cash flowFDMT Free cash flowFDMT Capital expendituresFDMT Return on equityFDMT Stock buybacksFDMT Dividends paidFDMT Total assetsFDMT Total liabilitiesFDMT Shareholders’ equityFDMT overview →